Power to the Patients cover art

Power to the Patients

Power to the Patients

By: Brandon Li
Listen for free

Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com315762 Biological Sciences Science
Episodes
  • How Neuroplasticity Is Shaping the Next Generation of Psychiatric Medicines

    How Neuroplasticity Is Shaping the Next Generation of Psychiatric Medicines
    May 13 2026
    Dr. Aaron Koenig, Chief Medical Officer at Delix Therapeutics, sheds light on a new class of medicines designed to promote neuroplasticity without the hallucinogenic effects associated with psychedelics. On this episode of Power to the Patients, Koenig explains to host Brandon Li how neuroplasticogens could provide scalable treatments for depression and other serious brain disorders, why separating plasticity from psychedelic experiences matters for clinical development, and how emerging biomarkers such as qEEG may help measure brain changes in patients. The conversation spans scientific rationale, clinical challenges, and long term potential of plasticity-based therapeutics in psychiatry and neurology.
    Show More Show Less
    34 mins
  • 70% Remission for Postpartum Depression? The Psychedelic Breakthrough

    70% Remission for Postpartum Depression? The Psychedelic Breakthrough
    Apr 30 2026
    Postpartum depression treatment advances with psychedelic therapy. Greg Mayes of Reunion Neuroscience discusses luvesilocin drug development. This episode explores how shorter-acting psilocybin analogs offer new hope for mothers. Greg highlights the success of the RECONNECT study and the path to FDA breakthrough designation.
    Show More Show Less
    36 mins
  • Why Psychiatry Is Finally Breaking Free From Dopamine

    Why Psychiatry Is Finally Breaking Free From Dopamine
    Apr 15 2026
    In this episode of Power to the Patients, host Brandon Li sits down with Ken Kramer, PhD, Vice President and Head of Neuropsychiatry Medical Affairs at Bristol Myers Squibb, to explore why psychiatry has lagged behind other therapeutic areas and what’s finally changing. Kramer explains how decades of reliance on dopamine-based antipsychotics shaped treatment, and why new mechanisms like muscarinic agonism are opening the door to safer, more effective options for patients with schizophrenia.
    Show More Show Less
    29 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet